What does this research mean for the field?

Triptolide inhibits renal fibrosis by promoting the PGC1α/PCK1-mediated renal gluconeogenesis pathway. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to determine how triptolide affects renal fibrosis via the PGC1α/PCK1 pathway.

March 2, 2026Frontiers in Bioscience-Landmark0 citationsOpen Access

Triptolide Inhibits Renal Fibrosis Through Promotion of PGC1α/PCK1-mediated Renal Gluconeogenesis

YWYanzhe Wang YJYing Jing LYLiuyi Yang

Key Points

This research aims to determine how triptolide affects renal fibrosis via the PGC1α/PCK1 pathway.
Investigated the impact of triptolide on renal fibrosis models
Analyzed expressions of PGC1α and PCK1
Measured levels of histone lactylation and renal inflammation indicators
Triptolide significantly increased PGC1α and PCK1 levels
Histone lactylation decreased in response to triptolide
Renal inflammation markers reduced after triptolide treatment

Abstract

Triptolide may inhibit renal fibrosis by increasing the PGC1α/PCK1 axis, thereby promoting renal gluconeogenesis. This cascade may reduce histone lactylation and renal inflammation, providing a mechanistic pathway for its anti-fibrotic effect.

问 AI

Bookmark

View Full Paper

Cite This Study

Wang et al. (Tue,) studied this question.

synapsesocial.com/papers/69a52e45f1e85e5c73bf1c65 https://doi.org/https://doi.org/10.31083/fbl47847

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

问 AI

Bookmark

View Full Paper